Fig. 5

Equivalent antitumor efficacy and persistence of CD19 CAR-T cells through melatonin supplementation in vivo. A Experimental design illustrating the comparison between groups receiving CD19 chimeric antigen receptor (CAR) T cells with or without melatonin supplementation in a mouse model of CD19-positive tumor xenografts (N = 10). B, C Assessment of tumor growth inhibition and overall tumor burden in indicated groups (N = 10). D Survival rate analysis of indicated groups (N = 10). Data are representative of 2 independent experiments